Johnson & Johnson (NYSE:JNJ) is a company that caught the attention of Jim Cramer. He recounted an insightful conversation he had with the company’s CEO, highlighting:
“What alternatives are out there? Last Friday, we had the pleasure of speaking with Joaquin Duato, the CEO of Johnson & Johnson, who shared an inspiring narrative concerning revolutionary cancer therapies and high-quality medical devices, particularly in cardiac health. Though I’ve had concerns regarding the talc-related lawsuits, I now believe that the dangers connected to the asbestos and baby powder allegations have peaked, especially as J&J has been successfully defending itself and intends to contest each case individually. Ultimately, I think plaintiffs will start to recognize that pursuing J&J is too expensive.”
Gil C/Shutterstock.com
Johnson & Johnson (NYSE:JNJ) focuses on developing a wide range of pharmaceuticals and medical devices, including solutions for immunology, oncology, neuroscience, infectious diseases, cardiovascular health, and pulmonary hypertension. Additionally, the company offers surgical solutions, orthopedic products, vision care, and neurovascular innovations.
While we see the investment potential in JNJ, we believe that specific AI-related stocks may provide even greater upside with lower risk exposure. If you’re in search of a highly undervalued AI stock that is well-positioned to take advantage of Trump-era tariffs and the trend toward onshoring, check out our complimentary report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published on Insider Monkey.
